- This event has passed.
Presenter(s): Jeanette M. Tetrault, MD FACP, Assistant Professor of Medicine Yale University School of Medicine
Jennifer Edelman, MD, MHS, Yale University School of Medicine
This September 10th webinar highlighted that people with opioid use disorders are commonly infected with Hepatitis C virus (HCV) and/or HIV. It is important that all providers delivering treatment to individuals with opioid use disorders understand appropriate prevention, screening and treatment strategies of HCV and HIV and specific considerations for people receiving opioid agonist therapy. This includes an understanding of the latest technology used for detection of HCV and HIV, appropriate use of highly effective antiviral therapy, and recognition of potential interactions with methadone, buprenorphine and naltrexone. A strong foundation in understanding HCV and HIV prevention and treatment strategies is important for all providers treating individuals with opioid use disorders.
The follow up October 22nd webinar featured a further discussion of these topics and addressed questions and comments from participants from both webinars. Click HERE to complete the archived October 22nd webinar.
- Be aware of screening and testing strategies for HCV and HIV;
- Discuss the natural history and transmission risk of HCV and HIV;
- Understand HCV and HIV prevention strategies;
- Review current treatment approaches for HCV and HIV and recognize important treatment considerations
The American Academy of Addiction Psychiatry (AAAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AAAP designates this enduring material for a maximum of (one) 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PC-based attendees Required: Windows® 8, 7, Vista, XP or 2003 Server
Mac®-based attendees Required: Mac OS® X 10